Keke Nie | Oncology | Best Researcher Award

Published on by China Scientist

Prof. Dr. Keke Nie | Oncology | Best Researcher Award 

Dr. Keke Nie is a dedicated medical oncologist specializing in thoracic radio-oncology. She currently serves as the Director of Oncology at Qingdao Central Hospital, University of Health and Rehabilitation Sciences. With extensive clinical experience in lung and gastrointestinal cancers, she has led numerous research initiatives focused on improving cancer treatment outcomes. Dr. Nie holds an MD from Weifang Medical University and an MS from Qingdao University Medical School. Her expertise spans clinical trial design, surgical procedures, and medical research, making her a key figure in advancing oncology care in China.

Prof. Dr. Keke Nie | Qingdao Central Hospital | China

Profile

SCOPUS

ORCID

Education

  • Dr. Keke Nie pursued her foundational medical training at Weifang Medical University in China, where she earned her medical degree. She continued her academic journey at Qingdao University Medical School, where she completed a master’s program in clinical medicine. Her formal education laid a strong foundation for her clinical practice and research in the fields of thoracic radio-oncology and medical oncology.

Experience

  • Dr. Nie currently serves as the Director of Oncology at Qingdao Central Hospital, affiliated with the University of Health and Rehabilitation Sciences. In this leadership role, she is actively involved in designing and implementing clinical research studies, particularly in lung cancer and gastrointestinal cancer. Prior to this, she worked for over a decade at Qingdao Cancer Hospital and Institute as an attending physician. There, she was responsible for patient care and clinical investigation, with a focus on lung, colon, breast, and ovarian cancers, especially in the post-surgical context. Her career reflects a continuous dedication to cancer treatment and patient-centered care.

Awards and Recognition

  • Dr. Nie’s appointment as Director of Oncology and her long-standing contributions to leading institutions in Qingdao reflect recognition of her clinical excellence and research capability. Her leadership in designing clinical studies indicates the trust placed in her expertise by the medical and scientific community.

Skills and Expertise

  • Dr. Nie is proficient in various software tools essential for medical research and documentation, including Microsoft Office, Sigmaplot, and Photoshop. She has practical knowledge of clinical trial protocols, including the preparation of new drug studies and the development of novel treatment techniques. In addition, she possesses hands-on surgical experience, particularly in general surgery, which supports her work in oncology care.

Research Focus 

  • Dr. Nie’s primary research interests lie in thoracic radio-oncology and medical oncology. She is especially focused on developing clinical research protocols and conducting studies that enhance treatment outcomes for lung and gastrointestinal cancers. Her experience bridges both clinical practice and laboratory-based research, providing her with a comprehensive understanding of cancer therapeutics.

Publications

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)
Authors: DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, M Shen
Journal: Autophagy

Protective mechanism of FSH against oxidative damage in mouse ovarian granulosa cells by repressing autophagy
Authors: M Shen, Y Jiang, Z Guan, Y Cao, L Li, H Liu, S Sun
Journal: Autophagy

Involvement of the up-regulated FoxO1 expression in follicular granulosa cell apoptosis induced by oxidative stress
Authors: M Shen, F Lin, J Zhang, Y Tang, WK Chen, H Liu
Journal: Journal of Biological Chemistry

miR-26b Promotes Granulosa Cell Apoptosis by Targeting ATM during Follicular Atresia in Porcine Ovary
Authors: F Lin, R Li, ZX Pan, B Zhou, DB Yu, XG Wang, XS Ma, J Han, M Shen
Journal: PLoS One

Melatonin protects mouse granulosa cells against oxidative damage by inhibiting FOXO1-mediated autophagy: Implication of an antioxidation-independent mechanism
Authors: M Shen, Y Cao, Y Jiang, Y Wei, H Liu
Journal: Redox Biology

Conclusion

  • Dr. Keke Nie is a self-motivated and diligent medical professional with extensive experience in thoracic radio-oncology and medical oncology. Her clinical insight, combined with a strong foundation in research and technical skills, makes her a valuable contributor to cancer treatment advancements. With a career marked by commitment to patient care and scientific rigor, she continues to play a pivotal role in shaping clinical oncology research and practice in China.

Dengke Bao | Tumor biology | Best Researcher Award

Published on by China Scientist

Prof. Dr. Dengke Bao | Tumor biology | Best Researcher Award 

Dengke Bao, Ph.D., is a professor, Ph.D. supervisor, and Deputy Dean at the School of Pharmacy, Henan University. He is a recipient of the Excellent Youth Fund Project of the Henan Natural Science Foundation and the 2022 China Postdoctoral Science Foundation Funding. His research focuses on mitochondria-related mechanisms in tumorigenesis, cancer progression, and immune regulation. He has published 20+ SCI-indexed papers in top journals like Oncogene and Cell Death & Disease and serves as an editorial member for Scientific Reports. His work provides new insights into tumor microenvironment remodeling and drug resistance in cancer therapy.

Prof. Dr. Dengke Bao | Henan University | China

Profile

SCOPUS ID

ORCID ID

🎓Education

  • Dengke Bao holds a Ph.D. and has established himself as a distinguished professor and Ph.D. supervisor. His academic journey has been marked by excellence, leading to his recognition as a Program for Central Plains Youth Top Talent and a recipient of multiple prestigious research grants.

👨‍🏫Experience

  • Currently serving as the Deputy Dean of the School of Pharmacy at Henan University, Dengke Bao has played a pivotal role in advancing molecular diagnostics and therapy. He is also the Deputy Director of the Henan Engineering Research Center for Molecular Diagnosis and Therapy of Esophageal Cancer and the Director of the Laboratory of Biomarkers and Liquid Biopsy in Kaifeng. His work has significantly contributed to understanding mitochondria-related mechanisms in tumorigenesis, cancer progression, and tumor immune regulation.

🏆Awards and Recognitions

  • Dengke Bao has been honored with numerous awards, including the Excellent Youth Fund Project of the Henan Natural Science Foundation and recognition as a Young Core Instructor of Henan. He was also a recipient of the 2022 China Postdoctoral Science Foundation Funding, highlighting his exceptional contributions to the field of oncology research.

💡Skills and Certifications

  • With a deep expertise in tumor biology and the tumor microenvironment, Dengke Bao specializes in investigating mitochondrial damage-associated molecular patterns (DAMPs) and their role in inflammatory responses and cancer therapy resistance. His research combines molecular biology, oncology, and immunology to uncover new therapeutic strategies for hepatocellular carcinoma (HCC) and other malignancies.

🔬 Research Focus

  • Dengke Bao’s research is centered on understanding how mitochondrial damage-associated molecular patterns influence the tumor microenvironment and immune regulation. His groundbreaking study demonstrated that sorafenib treatment in HCC induces the release of mitochondrial DNA into the tumor microenvironment, promoting M2 macrophage polarization through TLR9 activation and enhancing sorafenib resistance. His findings offer a new perspective on targeting mitochondrial DAMPs to reprogram tumor-associated macrophages, providing novel strategies to improve therapeutic efficacy and overcome drug resistance in cancer treatment.

 📚 Publications and Editorial Roles

  • Dengke Bao has authored over 20 SCI-indexed papers as a first or corresponding author in high-impact journals, including Oncogene, Journal of Experimental & Clinical Cancer Research, and Cell Death & Disease. He also serves as an editorial member for Scientific Reports, further solidifying his influence in the field of cancer research.

🌎Conclusion

  • Given his exceptional research contributions, leadership, and impact in oncology, Dengke Bao is a highly suitable nominee for the Research for Best Researcher Award. His work is not only innovative but also holds great promise for improving cancer treatment and patient outcomes, making him a deserving recipient of this prestigious recognition.

📖Publications

  • TEFM facilitates uterine corpus endometrial carcinoma progression by activating ROS-NFκB pathway

    • Authors: J. Lei, Q. Zhu, J. Guo, D. Bao, R. Guo
    • Journal: Journal of Translational Medicine, 2024

  • Tenofovir disoproxil fumarate mediates neuronal injury by inducing neurotoxicity

    • Authors: X. Yang, J. Zhang, Y. Cheng, H. Liu, D. Bao
    • Journal: European Journal of Clinical Microbiology and Infectious Diseases, 2023

  • PRRSV infection activates NLRP3 inflammasome through inducing cytosolic mitochondrial DNA stress

    • Authors: H. Li, X. Yang, Y. Song, B. Wan, D. Bao
    • Journal: Veterinary Microbiology, 2023